CVRx | Barostim™ | Heart Failure Device Implant
CVRx offers a heart failure therapy option with Barostim™, the world’s first neuromodulation device for heart failure management. Learn more now!
CVRx, Inc. (CVRX) Stock Price, News, Quote & History - Yahoo Finance
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases.
Our Company | About Us - CVRx
CVRx ® advances health for people everywhere, giving each patient a fuller life. CVRx ® pioneers unique therapies that harness and harmonize the body’s natural systems, benefiting society and making CVRx ® a universal role model in healthcare.
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 …
Jan 13, 2025 · CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate ...
Our Team | About Us - CVRx
Our people are our greatest strength. Meet the senior management and board of directors that make up the leadership at CVRx®.
CVRx Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch
6 days ago · CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the United States, Germany, and Other...
CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy?
3 days ago · The market expects CVRx (CVRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...
Investor Relations - CVRx
CVRx® is a leader in the development of safe and effective therapies to address unmet needs in cardiovascular disease. Headquartered near Minneapolis, Minn., CVRx is dedicated to improving patient outcomes, quality of life and overall cardiovascular health via our novel baroreceptor neuromodulation therapies.
Congestive Heart Failure treatment - Barostim
Barostim is the world’s first FDA-approved neuromodulation system designed for Congestive Heart Failure treatment. Turn Heart Failure into Heart Success.
FDA approves new device to improve symptoms in patients with advanced ...
The FDA granted approval of the Barostim Neo System to CVRx Inc. The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety ...
- Some results have been removed